Navigation Links
20% Off Your Entire Order of Scientific, Technical, Medical (STM) Titles Until the End of December at Chemical Publishing Company
Date:12/12/2012

Boston, Massachusetts (PRWEB) December 12, 2012

Chemical Publishing Company announces its holiday sale of 20% off of all in stock titles throughout our website: http://www.chemical-publishing.com

Use coupon code "DECEMBER12".

You can download a free preview for any of our titles by simply clicking on the look inside link listed on the page.

Chemical Publishing Company provides the Scientific, Technical, and Medical education and professional market with applied science and reference publications.

Chemical Publishing Co., Inc.
P.O. Box 676
Revere, MA 02151

Read the full story at http://www.prweb.com/releases/2012/12/prweb10227733.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
2. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
3. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
4. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
5. Molecular Detection Inc. Completes $1.5 Million Financing to Advance New Tests for Sepsis and GI Disorders
6. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
7. Potassium Iodide Sales Surge on Heels of Large Government Order
8. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
9. U.S. Senate Urged to Increase Federal Funding for Research into Hereditary Angioedema, a Rare and Serious Genetic Disorder
10. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
11. Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2020)... ... June 30, 2020 , ... ... insights, today announced that the launch of a new clinical diagnostics ... about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that ...
(Date:6/28/2020)... Md. (PRWEB) , ... June 26, 2020 , ... ... trade association representing security solutions providers, today announced its strong opposition to the ... The bill would impose a blanket ban on most federal use of nearly ...
(Date:6/23/2020)... ... 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today that ... during the American Association for Cancer Research Virtual meeting. One poster describes the ... single agent activity in KEAP1 mutant tumor models of NSCLC. , ...
(Date:6/11/2020)... ... , ... PathSensors Inc., a Baltimore biotechnology company, announced today ... funded by the National Institute of Food and Agriculture (NIFA) entitled “Food Safety ... was to engineer and develop a field-deployable instrument for portable pathogen and toxin ...
Breaking Biology Technology:
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While the ... economic downturn will only increase price pressures overall for the industry. The era of ... every product launch is critical. However, history shows that only a third of product ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... (MBS) has announced a publication detailing the use of its revolutionary NEXTGENPCR ... chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step RT-PCR ...
(Date:6/25/2020)... ... 2020 , ... eClinical Solutions LLC , a leading ... drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on randomized ... COVID-19. This is the first study of an XPO1 inhibitor in patients with ...
Breaking Biology News(10 mins):